Effect of perindopril on the myocardial energy consumption in patients with heart failure after myocardial infarction

摘要

Objective: To explore the clinical efficacy of perinodopril in the treatment of heart failurein patients after myocardial infarction and effect on the myocardial energy consumption.Methods: A total of 87 patients with heart failure after myocardial infarction who wereadmitted in our hospital from August, 2014 to October, 2015 were included in the studyand divided into the routine dose group (n=43, perinodopril 4 mg/d) and high dose group(n=44, perinodopril 8 mg/d) according to the long-term oral dose. All the patients were givenperinodopril, continuously for 6 months. The changes of blood pressure and serum biochemicalindicators before and after treatment in the two groups were compared. The changes of cardiacfunction indicators and myocardial energy consumption indicators before and after treatmentin the two groups were compared. 6MWT 6 months and 1 year after treatment in the twogroups was calculated. Results: The plasma BNP and H-FABP levels, LVEDD, LVESD,MEE, and cESS after treatment in the two groups were significantly reduced when comparedwith before treatment, and those in the high dose group were significantly lower than thosein the low dose group. LVEF and FS after treatment in the two groups were significantlyincreased, and those in the high dose group were significantly greater than those in the routinedose group. The seurm potassium level after treatment in the high dose group was significantlyelevated when compared with before treatment, but was not significantly different from thatin the routine dose group. SBP, DBP, and Scr levels after treatment in the two groups were notsignificantly changed. 6MWT 6 months and 1 year after treatment in the high dose group wassignificantly greater than that in the routine dose group. Conclusions: Perinodopril in a highdose can significantly reduce the plasma BNP and H-FABP levels in patients with heart failureafter myocardial infarction, inhibit the ventricular remodeling, promote the recovery of systolicfunction, reduce the myocardial energy consumption, and will not affect the blood pressure,serum potassium, and renal function, with efficacy significantly superior to that in a low dose;moreover, it has a certain safety.